Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ENGN files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsenGene reports 54% complete response in Phase 2 bladder cancer trial, targets 2H 2026 BLA
Filed July 17, 2026 · Period ending July 17, 2026 · ~1 min read
Key Changes
-
high
Interim Phase 2 data showed 54% complete response rate for detalimogene in BCG-unresponsive bladder cancer, with 96.8% of patients free from progression to advanced disease (125 patients, 5.5-month median follow-up).
Exhibit 99.1 view on EDGAR → -
high
Company expects to file BLA in second half 2026 following 12-month pivotal cohort data, with potential FDA approval and platform designation in 2027. FDA previously indicated Phase 2 data may potentially support BLA approval.
Exhibit 99.1 view on EDGAR → -
high
Safety profile showed 91.3% of treatment-related adverse events were Grade 1-2, with only 4.8% of patients experiencing Grade 3+ events. Dose interruptions and discontinuations each occurred in 2.4% of patients.
Exhibit 99.1 view on EDGAR → -
high
Enrolled first patients in new surfactant combination cohort (up to 80 patients) after preclinical data showed 9-fold increase in IL-12 expression with polidocanol bladder rinse prior to detalimogene.
Exhibit 99.1 view on EDGAR → -
medium
Cash position of $285 million expected to provide operating flexibility through BLA filing and potential approval, reducing near-term financing risk.
Exhibit 99.1 view on EDGAR →
Summary
enGene disclosed interim Phase 2 results for detalimogene, its investigational gene therapy for BCG-unresponsive high-risk bladder cancer. The primary endpoint showed a 54% complete response rate at any time, with strong durability metrics: 96.8% of patients remained free from progression to advanced disease and 90.4% avoided cystectomy.
The safety profile appears favorable, with over 90% of treatment-related adverse events being mild to moderate and only 4.8% of patients experiencing serious events. The company plans to file a BLA in the second half of 2026 based on 12-month pivotal cohort data, with potential approval in 2027.
The FDA has previously indicated that Phase 2 data may potentially support BLA approval, though this depends on final clinical testing results. enGene has also initiated a surfactant combination cohort after preclinical work showed a 9-fold increase in IL-12 expression, suggesting potential for improved efficacy. With $285 million in cash, the company appears positioned to reach key regulatory milestones without immediate financing needs. Investors should watch for the 12-month durability data and BLA submission timing in the second half of 2026.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
enGene updated its corporate presentation under Regulation FD disclosure.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
On July 17, 2026, enGene Therapeutics Inc. updated its Corporate Presentation, a copy of which is furnished with this Current Report on Form 8-K as Exhibit 99.1 and incorporated into this Item 7.01 by reference.
The company furnished an updated corporate presentation under Item 7.01 Regulation FD Disclosure. This is a routine disclosure mechanism companies use to share investor materials publicly. The filing does not describe what changed in the presentation or disclose any specific business updates.
Event · Exhibit 99.1
enGene filed a corporate presentation deck disclosing interim Phase 2 clinical trial results for detalimogene, its investigational non-muscle-invasive bladder cancer therapy.
Added in current filing · view on EDGAR →
Surfactant Bladder Rinse Cohort: BCG-Unresponsive NMIBC CIS New Cohort ... First Patients Enrolled
The company has enrolled the first patients in a new clinical cohort evaluating detalimogene combined with a polidocanol surfactant bladder rinse. Preclinical data showed the surfactant increased IL-12 expression by over 9-fold and improved efficacy in animal models. The cohort targets up to 80 patients with BCG-unresponsive high-risk NMIBC and uses a 5-minute bladder rinse with 0.25% polidocanol prior to detalimogene administration, with the intravesical dwell time reduced from 60 to 30 minutes.
Added in current filing · view on EDGAR →
$285M in cash expected to provide significant operating flexibility through BLA filing and potential approval
The company disclosed it has $285 million in cash, which management expects will provide operating flexibility through the planned BLA filing and potential approval. This capital position is intended to support the company through key regulatory milestones without near-term financing needs.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 19, 2026 · How we verify